BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37338339)

  • 21. Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma.
    Porrata LF; Ristow KM; Habermann TM; Witzig TE; Colgan JP; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Nowakowski G; Thompson CA; Markovic SN
    Leuk Lymphoma; 2014 Dec; 55(12):2728-38. PubMed ID: 24547705
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical benefit of R-CHOP without splenectomy in stage I primary splenic diffuse large B-cell lymphoma.
    Rajendran T; Kini JR; Abna A; Prasad K
    BMJ Case Rep; 2022 Jan; 15(1):. PubMed ID: 34983812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary cutaneous diffuse large B cell lymphoma-other successfully treated by the combination of R-CHOP chemotherapy and surgery: A case report and review of literature.
    Jia J; Li W; Zheng Y
    Medicine (Baltimore); 2017 Feb; 96(8):e6161. PubMed ID: 28225499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary diffuse large B-cell lymphoma of the prostate: a case report and review of the literature.
    Ren M; Liu Y
    J Med Case Rep; 2021 Nov; 15(1):546. PubMed ID: 34727993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rare malignant ulcer related to primary intestinal diffuse large B-cell lymphoma: A case report.
    Jia N; Tang Y; Li Y
    Medicine (Baltimore); 2020 Feb; 99(6):e18590. PubMed ID: 32028388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BEACOPP escalated and rituximab in the treatment of Hodgkin lymphoma occurring concurrently with diffuse large B-cell non-Hodgkin lymphoma.
    Palickova M; Mocikova H; Vernerova Z; Campr V; Kozak T
    Leuk Lymphoma; 2013 Sep; 54(9):2081-2. PubMed ID: 23311295
    [No Abstract]   [Full Text] [Related]  

  • 27. A case of primary adrenal diffuse large B-cell lymphoma achieving complete remission with rituximab-CHOP chemotherapy.
    Kim KM; Yoon DH; Lee SG; Lim SN; Sug LJ; Huh J; Suh C
    J Korean Med Sci; 2009 Jun; 24(3):525-8. PubMed ID: 19543522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.
    Horn H; Ziepert M; Becher C; Barth TF; Bernd HW; Feller AC; Klapper W; Hummel M; Stein H; Hansmann ML; Schmelter C; Möller P; Cogliatti S; Pfreundschuh M; Schmitz N; Trümper L; Siebert R; Loeffler M; Rosenwald A; Ott G;
    Blood; 2013 Mar; 121(12):2253-63. PubMed ID: 23335369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-operative Management of Spontaneous Gastropleural Fistula Caused by Primary Gastric Diffuse Large B-cell Lymphoma.
    Suzaki K; Kobayashi M; Kosugi N
    Intern Med; 2023 Nov; 62(21):3237-3240. PubMed ID: 37032089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Spectrum of MYC Alterations in Diffuse Large B-Cell Lymphoma.
    Xia Y; Zhang X
    Acta Haematol; 2020; 143(6):520-528. PubMed ID: 32074595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.
    Visco C; Tzankov A; Xu-Monette ZY; Miranda RN; Tai YC; Li Y; Liu WM; d'Amore ES; Li Y; Montes-Moreno S; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Wang HY; Dunphy CH; His ED; Zhao XF; Choi WW; Zhao X; van Krieken JH; Huang Q; Ai W; O'Neill S; Ponzoni M; Ferreri AJ; Kahl BS; Winter JN; Go RS; Dirnhofer S; Piris MA; Møller MB; Wu L; Medeiros LJ; Young KH
    Haematologica; 2013 Feb; 98(2):255-63. PubMed ID: 22929980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.
    Walewski J; Paszkiewicz-Kozik E; Michalski W; Rymkiewicz G; Szpila T; Butrym A; Giza A; Zaucha JM; Kalinka-Warzocha E; Wieczorkiewicz A; Zimowska-Curyło D; Knopińska-Posłuszny W; Tyczyńska A; Romejko-Jarosińska J; Dąbrowska-Iwanicka A; Gruszecka B; Jamrozek-Jedlińska M; Borawska A; Hołda W; Porowska A; Romanowicz A; Hellmann A; Stella-Hołowiecka B; Deptała A; Jurczak W
    Br J Haematol; 2020 Mar; 188(6):898-906. PubMed ID: 31792945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy.
    Binkley MS; Hiniker SM; Wu S; Natkunam Y; Mittra ES; Advani RH; Hoppe RT
    Leuk Lymphoma; 2016; 57(3):604-8. PubMed ID: 26159046
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
    Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
    J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy.
    Niitsu N; Tamaru J; Yoshino T; Nakamura N; Nakamura S; Ohshima K; Nakamine H; Okamoto M
    Ann Hematol; 2011 Feb; 90(2):185-92. PubMed ID: 20809421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL).
    Jung SH; Lee JJ; Kim WS; Lee WS; Do YR; Oh SY; Kim MK; Mun YC; Shin HJ; Kwak JY; Kang HJ; Won JH; Kwon JH; Park E; Suh C; Yang DH
    Eur J Haematol; 2015 Jun; 94(6):504-10. PubMed ID: 25288018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients.
    Koh YW; Hwang HS; Park CS; Yoon DH; Suh C; Huh J
    Leuk Lymphoma; 2015; 56(9):2630-6. PubMed ID: 25573205
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnosis and Management of Cutaneous B-Cell Lymphomas.
    Malachowski SJ; Sun J; Chen PL; Seminario-Vidal L
    Dermatol Clin; 2019 Oct; 37(4):443-454. PubMed ID: 31466585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Efficacy of surgery and rituximab in primary gastric diffuse large B-cell lymphoma].
    Huang HW; Jiang YB; Fu TW; Xu T; Chen XC; Jin ZM; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2016 Jul; 37(7):602-6. PubMed ID: 27535862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.